Author

S. S. Mun

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Assay:proteomics· 2

Frequent Co-Authors

D. A. Scheinberg· 2 shared T. Dao· 2 shared A. Charles· 1 shared A. Daman· 1 shared C. Bourne· 1 shared C. M. Bourne· 1 shared C. Steidl· 1 shared K. Takata· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

D. A. Scheinberg

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Unmasking the cryptic immunopeptidome of EZH2 mutated diffuse large B-cell lymphomas through combination drug treatment

C. M. Bourne, S. S. Mun, T. Dao, Z. E. H. Aretz, R. S. Gejman, A. Daman, K. Takata, C. Steidl, M. G. Klatt, D. A. Scheinberg

The paper identifies tumor-specific MHC ligands in EZH2-mutated DLBCLs by combining epigenetic drugs and interferon gamma, expanding the immunopeptidome for immunotherapy targets.

bioRxiv · Sep 1, 2021 · PreprintImmunology

Low-Dose CDK4/6 Inhibitors Induce Presentation of Pathway Specific MHC ligands as Targets for Cancer Immunotherapy

A. Charles, C. Bourne, S. S. Mun, T. Dao, Z. Aretz, T. Korontsvit, M. Klatt, D. A. Scheinberg

This study shows low-dose CDK4/6 inhibitors increase HLA ligand presentation from cell cycle proteins, creating potential targets for immunotherapy in breast cancer.

bioRxiv · Jun 18, 2020Cancer Biology